Accessibility Menu
CareDx logo

CareDx

(NASDAQ) CDNA

Current Price$39.73
Market Cap$2.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+303%
5 Year-50%
1 Year+236%
1 Month+69%
CareDx last closing stock price
MetricPriceDate
Last closeUSD 39.732026-07-17
CareDx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+39.35%USD 28.512026-07-10
1 month+69.21%USD 23.482026-06-17
3 month+85.48%USD 21.422026-04-17
Year to date+110.88%USD 18.842025-12-31
1 year+236.41%USD 11.812025-07-17
3 year+285.35%USD 10.312023-07-18
5 year-49.6%USD 78.832021-07-16
Since inception+303.4%USD 10.002014-07-18

CareDx Financials at a Glance

Market Cap

$2.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$412.82M

Net Income (TTM)

-$8.19M

EPS (TTM)

-$0.15

P/E Ratio

-261.78

Dividend

$0.00

Beta (Volatility)

1.58 (High)

Price

$39.73

Volume

1,763,665.429

Open

$37.79

Previous Close

$39.73

Daily Range

$37.74 - $40.47

52-Week Range

$11.26 - $40.47

Estimated Earnings Date

Aug 5, 2026

CDNA News

SellAlert-Red.png

CareDx's CEO Sells 17K Shares

Lawrence Rothman, CFAJun 21, 2026
SellAlert-Red.png

CareDx's CEO Conducts Multiple Sale of Shares Towards the End of January 2026

Adé HennisFeb 1, 2026
SellAlert-Purple.png

CareDx President and CEO Sells 19,000 Shares for $412,000

Sarah SidlowJan 30, 2026
Foolcom-Featured.png

CareDx (CDNA) EPS Beats Sales Gain 14%

Motley Fool Markets TeamAug 6, 2025
using a stethoscope listen to the heartbeat of patient (1)

Why Shares of CareDx Are Jumping Friday

James HalleyJul 7, 2023
21110

These Charts Explain Why I'm Holding This Healthcare Company

Patrick BafumaApr 29, 2022
investor-looking-for-stocks-on-computer-getty

3 Unstoppable Growth Stocks You Can Buy for Less Than $100 Right Now

Cory RenauerNov 29, 2021
100-bill-held-by-a-smart-investor-getty

Why Cathie Wood Is Buying Beaten-Down CareDx

Cory RenauerNov 6, 2021
Page 1

CDNA: Motley Fool Moneyball Superscore

60

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About CareDx

CareDx, Inc. is a precision medicine company that specializes in diagnostics for transplant patients, offering innovative, non-invasive testing solutions. Based in Brisbane, California, the company focuses on enhancing patient care by improving transplant monitoring and outcomes through its genomics-based technologies.

Products and Services

AlloSure Kidney: A donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients.

AlloMap Heart: A gene expression solution for heart transplant patients.

AlloSure Heart: A dd-cfDNA solution for heart transplant patients.

AlloSure Lung: A dd-cfDNA solution for lung transplant patients.

AlloCell: A surveillance solution for patients undergoing cell therapy.

What Makes CareDx, Inc Special

CareDx, Inc. differentiates itself with its specialized focus on the transplant market, providing proprietary diagnostics that reduce complications and improve patient outcomes. Its emphasis on non-invasive solutions and strong barriers to entry due to complex diagnostics give it an edge over competitors.

Five Things You Need to Know

CareDx is a leader in genomics-based transplant diagnostics with a strong commitment to precision medicine.

The company offers non-invasive testing solutions like AlloSure and AlloMap, improving transplant monitoring.

CareDx has formed strategic partnerships for research and development, enhancing its market position.

It has a global footprint, supported by operations in the U.S., Australia, and Sweden.

CareDx's growth strategies include expanding test offerings, increasing hospital partnerships, and leveraging digital health platforms.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

765

CEO

John W. Hanna, MBA

Website

www.caredx.com

Headquarters

Brisbane, CA 94080, US

CDNA Financials

Key Financial Metrics (TTM)

Gross Margin

68.56%

Operating Margin

-3.20%

Net Income Margin

-1.98%

Return on Equity

-2.61%

Return on Capital

-6.38%

Return on Assets

-1.99%

Earnings Yield

-0.38%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.66M

Volume

1.76M

Avg. Volume

872.47K

Financials (TTM)

Gross Profit

$283.04M

Operating Income

-$13.20M

EBITDA

$10.70M

Operating Cash Flow

$72.95M

Capital Expenditure

-$7.76M

Free Cash Flow

$65.19M

Cash & ST Invst.

$187.18M

Total Debt

$24.50M

CareDx Performance Analysis

CareDx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 321,793,0008.6%
20232023-12-31USD 280,324,000-12.9%
20242024-12-31USD 333,785,00019.1%
20252025-12-31USD 379,805,00013.8%
CareDx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-302.4%
Q32025-09-3015.4%
Q42025-12-318.3%
Q12026-03-318.6%
CareDx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.44144.8%
20232023-12-31USD -3.54146.3%
20242024-12-31USD 0.93N/A
20252025-12-31USD -0.40N/A
CareDx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3015.8%
Q32025-09-30119.5%
Q42025-12-31-356.4%
Q12026-03-31162.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$117.70M

+39.0%

Gross Profit

$84.07M

+49.4%

Gross Margin

71.43%

N/A

Market Cap

$2.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.72M

N/A

Employees

765

N/A

Net Income

$2.81M

+127.1%

EBITDA

$8.10M

+363.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$187.18M

-18.9%

Total Debt

$24.50M

-19.1%

Accounts Receivable

$44.59M

-37.6%

Inventory

$26.40M

+15.2%

Long Term Debt

$17.84M

-25.9%

Short Term Debt

$6.66M

+7.3%

Return on Assets

-1.99%

N/A

Return on Invested Capital

-3.98%

N/A

Free Cash Flow

$514.00K

+101.8%

Operating Cash Flow

$4.33M

+116.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRVIMaravai LifeSciences Holdings, Inc.
$7.24+2.12%
VIRVir Biotechnology, Inc.
$9.43+0.32%
PSNLPersonalis, Inc.
$15.39-1.22%
CSTLCastle Biosciences, Inc.
$24.16-0.29%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NVDANvidia
$202.81-0.02%
INTCIntel
$95.04-0.02%

Questions About CDNA

What is the current price of CareDx?

CareDx is trading at $39.73 per share.

What is the 52-week range for CareDx?

Over the past 52 weeks, CareDx has traded between $11.26 and $40.47.

How much debt does CareDx have?

As of the most recent reporting period, CareDx reported total debt of $24.50M.

How much cash does CareDx have on hand?

CareDx reported $77.92M in cash and cash equivalents in its most recent financial results.

What is CareDx’s dividend yield?

CareDx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services